Your Primer to Healthcare Mergers and Acquisitions

The Opportunity Is Here: What The Data May Be Saying

May 26, 2015

by Tom Schramski

By Tom Schramski, PhD, CM&AA

Volume 2 Issue 11, May 26, 2015

GF Data®, one of the premier data sources in private M+A transactions in the $10-250 million range, recently released its data on private equity deals for the Trailing Twelve Months (TTM) that ended on March 31, 2015. There are some emerging insights that today’s healthcare business executives should consider:

  • Valuations of businesses with three unique factors are often appreciably higher than those entities without the same factors in play.  These factors include above average financial performance, a strong management solution after the closing of the transaction, and institutional vs. individual/family ownership prior to the business sale.
  • Valuations for “add on” businesses (those smaller businesses that are acquired to enhance the investment in a much larger business platform) are now approaching, and even surpassing, some platform valuation multiples of EBITDA (see Chart 3).
  • Healthcare EBITDA multiples remain relatively high, especially for businesses in the $25-50 million Total Enterprise Value (TEV) range (8.3x), as well as deals in the $100-250 million range (9.9x) (see Chart 16).



What does this all mean for a healthcare business owner considering a transition?  Of course, it always depends on multiple factors not incorporated in this data, including personal goals and objectives.  Yet, all things given, we know the healthcare marketplace remains active with abundant opportunities for successful transactions involving relatively small companies.  It is also clear that higher value is given to consistently profitable healthcare businesses that have a strong team in place and are operated as a business.  When buyers can clearly see your value, you will be rewarded for the clarity.

Note: GF Data® provides data on private equity-sponsored M+A transactions with enterprise values of $10 to 250 million.  GF Data® collects transaction information from private equity groups (PEGs) on a blind and confidential basis.  Information from GF Data® may not be used in work product or republished in any form without written permission of GF Data Resources, LLC or Vertess Advisors, LLC.

Tom Schramski

Tom Schramski PhD, CM&AA


Tom was the Founder and Managing Partner of VERTESS. He was a Certified Merger & Acquisition Advisor (CM&AA), consultant, and Licensed Psychologist with over 35 years of very successful national experience in the healthcare marketplace, including co-founding and building a $25 million behavioral health/disabilities services company. Tom represented sellers and investors across the healthcare spectrum and was recognized for his executive leadership in the 2005 Entrepreneur of the Year issue of Inc. Tom passed away in December 2018.

We can help you with more information on this and related topics. Contact us today!

Committed to Constant Improvement?

Subscribe to our bi-weekly newsletter – SalientValue

No Spam Ever. We Promise.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram